Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort

ConditionsObesity Aging Aging Problems Metabolic Syndrome

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorThomas Scherer

About this trial

The goal of this prospective observational study is to identify and validate blood based aging biomarkers in relation to cardiometabolic phenotypes of young and old, female and male subjects with or without obesity.

The main question is to gain insights into the interaction of obesity related metabolic alteration and aging, and the relevance of loss of metabolic control in the development of age-related diseases in order to build a foundation for targeted drug- and lifestyle interventions in future studies.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 - 35 years

Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months)

Age 18 - 35 years

BMI ≥ 28kg/m2 (≥ 12 months)

Disqualifiers

Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm])

Special diets (i.e. ketogenic diet and time-restricted eating)

Clinically significant metabolic or endocrine disorders

Claustrophobia

Trial population

Community sample from eastern Austria.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

comprehensive metabolic phenotyping
Diagnostic test
The investigators will employ state of the art techniques to metabolically phenotype the study groups using brain, cardiac and whole body magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), wearables, optical coherence tomography longitudinally. In addition, a battery of patient reported outcome measures will be used to explore psychosocial aspects of aging.

Treatment groups

650 Participants

are divided into 5 treatment groups

Group A: Lean, young adults1 intervention

Group B: Overweight, young adults1 intervention

Group C: Lean, older adults1 intervention

Group D: Overweight, older adults1 intervention

Group E: Nonagenerians Age ≥ 901 intervention

Trial outcomes

Primary outcomes

Biological age: Epigenetic and clinical clocks

Epigenetic and clinical clocks (i.e. LinAge2, PheoAge) will be measured assessing DNA methylation in whole blood and standard laboratory parameters. The investigators speculate that the biological age is accelerated in obesity/overweight persons independent of chronological age.

Time frame

every 3 years

Secondary outcomes

Magnetic resonance spectroscopy

Hepatic lipid content

Time frame

every 3 years

Magnetic resonance imaging

Whole body fat distribution

Time frame

every 3 years

Other outcomes

Vibration-controlled transient elastography

Liver stiffness, Hepatic lipid content

Time frame

every 3 years

Body composition

Air Displacement Plethysmograph with BodPod

Time frame

every 3 years

Continuous glucose monitoring

Continuous blood glucose monitoring over 2 weeks will be performed

Time frame

every 3 years

Retina scans

Optical coherence tomography angiography

Time frame

every 3 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Thomas Scherer

Lead sponsor

Medical University of Vienna

Sponsor institution

Medical University of Graz

Collaborator

University of Graz

Collaborator

Source ClinicalTrials.gov

Apply now